34 results about "Steatosis" patented technology

This invention discloses a low-astringency prickly pear lactic acid bacteria fermented beverage and its application in lowering blood lipids and antioxidation, relating to the fields of microbial application and food fermentation technology. The fermented beverage of this invention uses prickly pear juice as raw material and is prepared by fermentation with *Lactobacillus plantarum* R-21. It can significantly reduce the tannin content of prickly pear juice, improve taste, and increase the polysaccharide content and antioxidant properties of the beverage. In vivo experiments show that it can reduce the levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in mouse liver and serum, inhibit fat accumulation and fatty degeneration in liver cells, and enhance the activity of antioxidant enzymes in the liver, demonstrating important application value in lowering blood lipids and antioxidation.

Disclosed are compounds of Formula I as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

This application discloses the application of pyridostigmine in the preparation of drugs for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Validation was conducted using animal models of NAFLD induced by three different etiologies: methionine-choline deficiency diet, high-fat diet, and leptin gene knockout. Pyridostigmine significantly improved vagal nerve activity in the model animals (e.g., improving high-frequency and baroreflex sensitivity in heart rate variability), effectively corrected serum lipid metabolism disorders (reducing LDL cholesterol), alleviated hepatocyte damage (reducing ALT and AST), and at the histopathological level, reduced hepatic steatosis, decreased inflammatory cell infiltration, and inhibited collagen deposition, thereby achieving the prevention and treatment of NAFLD.

A system for managing liver disease, the system comprising an electronic medical record system comprising a plurality of patient records. The system comprising a patient management platform configured to access the electronic medical record (EMR) system to retrieve medical records of one or more patients, analyze the medical records to selectively identify data related to a liver condition, interface with one or more data analysis platforms configured to receive and analyze the data related to a liver condition. Based on analysis by the patient management interface and / or the data analysis platforms, a display is generated comprising: specific liver-related patient attributes and conditions, and at least one of: a liver health prognosis or a recommended treatment for addressing the liver condition corresponding to the one or more patients. The liver condition can comprise one or more of: cancer, cirrhosis, liver failure, fatty liver disease, steatosis, ischemia, and / or hepatitis.

This invention discloses the use of the SLC7A5 gene or its encoded product as a target in the preparation of drugs for the prevention and / or treatment of metabolic dysfunction-related fatty liver disease (MASLD). This invention reveals for the first time that SLC7A5 is a key node regulating hepatic lipid metabolism, and inhibiting its expression or function can significantly reduce hepatic steatosis, inflammation, and fibrosis. Specifically, this invention relates to pharmaceutical compositions containing SLC7A5 inhibitors, said inhibitors including small molecule compounds, specific antibodies, nucleic acid interfering agents, or gene editing tools. Furthermore, this invention provides a drug screening method for MASLD, which combines molecular docking virtual screening technology with target specificity verification steps, and the application of SLC7A5 as a biomarker in disease diagnosis, staging, and efficacy monitoring. This invention provides definite new targets and candidate drugs with well-defined mechanisms for the clinical diagnosis and treatment of MASLD.

An antisense oligonucleotide targeting inhibin βE (INHβE) and the use thereof. The antisense oligonucleotide molecule has a length of 16-22 bases. The antisense oligonucleotide molecule can target mRNA and pre-mRNA sequences of INHβE and reduce the expression thereof. The antisense oligonucleotide molecule has the following uses: (1) in the preparation of a preparation for inhibiting the expression level of INHβE; or (2) in the treatment of diseases caused by hepatic steatosis and / or insulin resistance.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

This invention relates to a *Malus toringo* exosome-like nanoparticle, its preparation method, and its uses, belonging to the pharmaceutical field. The *Malus toringo* exosome-like nanoparticles of this invention are derived from the plant *Malus toringo*, belonging to the Rosaceae family. Malus toringoides (Rehd.) Hughes and Begonia variegated Malus transitoria Using fresh leaves of *Batal.* Schneid. as raw material, exosome-like nanoparticles were extracted from *Batal.* Schneid. using differential centrifugation and ultra-high speed centrifugation. The *Batal.* Schneid. exosome-like nanoparticles of this invention exhibit significant hypoglycemic and lipid-regulating effects, significantly reducing fasting blood glucose, improving glucose tolerance, increasing insulin sensitivity, and lowering serum TC and TG levels; they also improve liver pathological damage, significantly reducing hepatic lipid accumulation and steatosis, with effects superior to rosiglitazone; while lowering blood glucose and regulating lipids, the *Batal.* Schneid. exosome-like nanoparticles of this invention also inhibit weight gain without the risk of liver damage, demonstrating good comprehensive therapeutic potential.

The present disclosure provides methods of treating a steatotic liver disease associated with metabolic dysfunction, such as metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated fatty livers disease (MAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD). The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.

This invention relates to the application of PRMT4 inhibitors in the preparation of drugs for treating metabolic-associated steatohepatitis (MASH), belonging to the field of fatty liver disease treatment technology. This invention is the first to discover that PRMT4 inhibitors can serve as a novel drug target for treating MASH. Cellular experiments show that PRMT4 inhibitors inhibit palmitic acid-induced hepatocyte steatosis. Animal experiments confirm that PRMT4 inhibitors can improve hepatic fat deposition, inflammatory response, hepatocyte damage, fibrosis, and insulin resistance in high-fat fed mice, and reduce liver tissue and serum triglyceride and transaminase levels. This invention finds that PRMT4 inhibitors mainly inhibit the activation of YAP, a key transcriptional activator involved in lipid and inflammatory metabolism, and the expression of its downstream target genes. Therefore, PRMT4 inhibitors can be used to prepare drugs for treating MASH, with definite and significant efficacy, and have promising medical application prospects.

Provided are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

This invention discloses a GLP-1R agonist, its synthesis method, and its uses, belonging to the pharmaceutical field. This invention provides a GLP-1R agonist with the structure shown in formula (I), which can be used to treat human GLP-1R-mediated diseases or conditions, such as type 2 diabetes, prediabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatosis, and cardiovascular diseases.

The application discloses an ex vivo perfusion preservative solution for improving the curative effect of liver transplantation. 1000 mL of the ex vivo perfusion preservative solution comprises the following components: 20-60 mg of oxamic acid, 2 g of sodium penicillin, 15000-20000 U of heparin, 20 mg of N-acetyl cysteine, and HTK liquid is supplemented to 1000 mL. The ex vivo perfusion preservative solution for improving the curative effect of normal liver and fatty degeneration liver transplantation can effectively improve the liver injury caused by I / R. Compared with the HTK liquid used at present, the ex vivo perfusion preservative solution has better protection effect, and has a good application prospect for the preservation of donor liver in liver transplantation surgery, especially the fatty degeneration liver.

The present application relates to the technical field of image data processing, and more particularly, to a fat liver lesion image analysis method based on color texture features, comprising: extracting a rat liver region through image segmentation, converting to a CIELAB color space to separate luminance, red-green chroma and yellow-blue chroma components; calculating local texture difference features based on a pixel space neighborhood, coupling luminance values to construct pixel-level effectiveness weights to suppress specular reflection; using pixel-level effectiveness weights to update K-Means clustering centers, distinguishing between steatosis regions and non-lesion regions, and counting pixel points to realize analysis of fat liver lesion images. The present application accurately suppresses optical noise interference, improves clustering accuracy, and improves fat liver lesion analysis accuracy, providing reliable technical support for drug efficacy evaluation and pathological mechanism research.

The present disclosure is related to ex vivo methods and devices for identifying a presence of or predicting a risk for a condition in a subject, wherein the risk or condition is correlated with an oxidation-redox potential (ORP) of a biological sample obtained from the subject, such as a fecal sample. The methods and devices of the present disclosure can be used to diagnose and monitor gut microbiome health and assess the risk and / or presence of conditions such as obesity, metabolic dysfunction associated steatotic liver disease (MASLD), type 2 diabetes, hyperlipidemia, hypertension, cardiovascular disease, a gut specific condition, irritable bowel syndrome, an inflammatory bowel disease, ulcerative colitis, Crohn's disease, a Clostridium difficile infection, or any combination thereof based on an ORP of the subject's sample.

Provided are compounds of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, to a patient in need thereof.

The application discloses the use of ACY-1 modulators as a therapeutic target for fatty liver disease and drug screening. By constructing a HepG2 cell lipid deposition model, it is found for the first time that ACY1 overexpression can exacerbate cell triglyceride accumulation; by constructing a MASH mouse model induced by a high-fat high-cholesterol high-fructose diet, it is found that ACY1 overexpression can exacerbate MASH progression; based on these findings, a drug screening method for preventing or treating fatty liver disease is constructed, and 2-hydroxyhexanoic acid (2-HHA) is screened out, which can significantly inhibit the in vitro enzyme activity of ACY1, and can alleviate abnormal cell triglyceride accumulation caused by palmitic acid-oleic acid stimulation at the cell and animal levels, and significantly improve the weight gain, liver lipid deposition, fatty degeneration, inflammatory infiltration and fibrosis of MASH mice induced by a high-fat high-cholesterol high-fructose diet, and the like, in addition, the inhibitor 2-hydroxyhexanoic acid can significantly reduce the abnormally increased serum ALT, AST and liver TC and TG of MASH mice.

The application belongs to the field of new use of medicines, and more particularly relates to application of Darapladib in preparation of medicines for preventing and treating metabolic dysfunction related fatty hepatitis. The application firstly finds that after treatment by Darapladib, the liver weight, liver / body ratio, serum total cholesterol, steatosis, ballooning, inflammatory infiltration and collagen deposition of MASH model mice are significantly reduced. The application expands the traditional use of Darapladib in cardiovascular diseases, and provides a new treatment strategy for MASH.

The application discloses a polysaccharide with lipid-lowering and weight-reducing effects, and a preparation method and application thereof. The polysaccharide is obtained by extracting a crude extract from plant raw materials and performing multi-stage separation and purification, and has a single component with lipid-lowering and weight-reducing effects. The polysaccharide can reduce or control weight gain, reduce fat content or lipid load, improve or restore liver morphology, inhibit or reduce liver weight gain, inhibit or reverse liver steatosis, improve sugar and lipid metabolism, improve intestinal flora structure and the like.

This invention discloses the application of acyl-resorcinol derivatives in the preparation of drugs or health products for the prevention and treatment of non-alcoholic steatohepatitis (NASH). Studies have shown that in an in vitro model of free fatty acid-induced normal human hepatocytes, these compounds can exert a hepatoprotective effect by reducing lipid accumulation in cells. The representative compound, hyperacmotone A, significantly reduces lipid accumulation in cells in a dose-dependent manner and regulates the expression of genes such as Pparα, Cpt1, and Fapp1. In a methionine-choline deficiency-induced mouse model, administration of hyperacmotone A can inhibit hepatic steatosis, reduce serum alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) levels, while simultaneously reducing hepatic triglyceride levels and increasing hepatic glutathione activity. This suggests a certain preventive and therapeutic effect on the occurrence and development of NASH.

This invention relates to a morel lectin, its preparation method, and its application, belonging to the field of biotechnology. The amino acid sequence of the morel lectin of this invention is shown in SEQ ID NO.1. The morel lectin is obtained by ultrafiltration, saturated ammonium sulfate precipitation, dialysis, microporous membrane filtration, Q Beads 6FF ion chromatography, dialysis, and freeze-drying of the supernatant after homogenizing morel mushrooms with water. The morel lectin is used to treat non-alcoholic fatty liver disease (NAFLD), inhibiting weight gain, reducing hepatomegaly, lowering blood lipid levels, improving obesity symptoms, reducing hepatic steatosis and liver function damage, and effectively treating NAFLD.

The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I): or a salt thereof. These compounds are TLR9 compounds suitable for use in the treatment, prevention or slowing of a fibrotic disease, such as liver fibrosis, kidney fibrosis, biliary fibrosis or pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic nephropathy, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

Provided are compounds of formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

Pharmaceutical compositions comprising a selective TGF-β inhibitor, such as a TGFβRII-Fc, are provided herein to prevent, reverse, reduce the occurrence of and / or treat fatty degeneration of skeletal muscle. Additionally, the selective TGF-β inhibitors may be used to inhibit fibro-adipogenic progenitor cell (FAP) differentiation into adipocytes.

Provided are compounds of Formula I, Formula Ib or Formula Ic and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, Formula Ib or Formula Ic, pharmaceutical compositions comprising compounds of Formula I, Formula Ib or Formula Ic, and methods of using these compounds to treat hepatic steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The present disclosure generally relates to compositions and methods that can treat or prevent nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatitis and / or hepatic steatosis (fatty liver). More specifically, the present disclosure relates to administering a formulation comprising a combination of at least one glycine or functional derivative thereof, and / or at least one N-acetylcysteine or functional derivative thereof, and at least one thymol and / or carvacrol, in an amount effective to decrease liver steatosis. The formulation can concomitantly decrease liver damages, in particular those observed in patients with NAFLD.

This invention discloses the application of Xinnaoning capsules in the preparation of drugs for treating non-alcoholic fatty liver disease (NAFLD), belonging to the field of pharmaceutical technology. Using a high-fat diet-induced NAFLD model in SD rats, this invention demonstrates that Xinnaoning capsules can significantly reduce liver and serum total cholesterol and triglyceride levels, lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to protect liver function, downregulate inflammatory factors such as tumor necrosis factor-α, interleukin-6, and interleukin-1β, improve insulin resistance, and alleviate hepatic steatosis and inflammatory damage in a dose-dependent manner, with higher doses showing better effects. This invention provides a safe, multi-target traditional Chinese medicine treatment for NAFLD, expands the clinical indications of Xinnaoning capsules, and has significant academic value and clinical application prospects.